0.6366
price up icon2.17%   0.0135
after-market 시간 외 거래: .67 0.0334 +5.25%
loading
전일 마감가:
$0.6231
열려 있는:
$0.6232
하루 거래량:
464.59K
Relative Volume:
0.74
시가총액:
$81.96M
수익:
-
순이익/손실:
$-26.91M
주가수익비율:
-2.8936
EPS:
-0.22
순현금흐름:
$-19.57M
1주 성능:
+0.33%
1개월 성능:
-15.55%
6개월 성능:
-56.10%
1년 성능:
-53.53%
1일 변동 폭
Value
$0.6104
$0.655
1주일 범위
Value
$0.5914
$0.655
52주 변동 폭
Value
$0.5526
$1.81

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name
명칭
Atossa Therapeutics Inc
Name
전화
206.588.0256
Name
주소
10202 5TH AVENUE NE, SEATTLE, WA
Name
직원
13
Name
트위터
@atossainc
Name
다음 수익 날짜
2025-03-25
Name
최신 SEC 제출 서류
Name
ATOS's Discussions on Twitter

ATOS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ATOS
Atossa Therapeutics Inc
0.6366 81.96M 0 -26.91M -19.57M -0.22
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2018-01-26 개시 Maxim Group Buy

Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스

pulisher
Apr 11, 2025

Atossa Therapeutics (ATOS) Partners with Nona Biosciences to Adv - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

Nona Biosciences and Atossa Therapeutics Partner to Discover Nex - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - The Manila Times

Apr 10, 2025
pulisher
Apr 10, 2025

Revolutionary Breast Cancer Treatment Alliance: Next-Gen Antibody Platform Powers New Research Initiative - Stock Titan

Apr 10, 2025
pulisher
Apr 08, 2025

Atossa Therapeutics (NASDAQ:ATOS) & Pharming Group (OTCMKTS:PHGUF) Critical Comparison - Defense World

Apr 08, 2025
pulisher
Apr 07, 2025

Atossa Therapeutics says Intas Pharmaceuticals Filed Petition For Post Grant Review Against Co- SEC Filing - marketscreener.com

Apr 07, 2025
pulisher
Apr 03, 2025

Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress - MSN

Apr 03, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Lowers Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

Atossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on Monday - Defense World

Mar 31, 2025
pulisher
Mar 29, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025
pulisher
Mar 29, 2025

Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock By Investing.com - Investing.com Canada

Mar 29, 2025
pulisher
Mar 29, 2025

Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

Atossa Therapeutics (NASDAQ:ATOS) Earns Buy Rating from HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 26, 2025

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth - Yahoo

Mar 26, 2025
pulisher
Mar 26, 2025

Atossa Therapeutics Inc (ATOS) Q4 2024 Earnings Call Highlights: - GuruFocus

Mar 26, 2025
pulisher
Mar 26, 2025

Atossa Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 26, 2025
pulisher
Mar 25, 2025

Atossa Therapeutics’ Strategic Focus on Z-endoxifen for Breast Cancer Drives Buy Rating - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings call transcript: Atossa Genetics Q4 2024 beats EPS forecast - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Atossa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

Atossa Therapeutics Inc Reports Q4 EPS of -$0.06, Aligning with Estimates; Revenue Remains at $0 Million - GuruFocus

Mar 25, 2025
pulisher
Mar 25, 2025

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings Scheduled For March 25, 2025 - Benzinga

Mar 25, 2025
pulisher
Mar 23, 2025

Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Tuesday - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Atossa Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 20, 2025

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

Atossa Therapeutics to Host Conference Call for Q4 and Full-Year 2024 Financial Results on March 25, 2025 - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Atossa Therapeutics Earnings: Key Q4 and 2024 Results Coming March 25How to Listen Live - StockTitan

Mar 20, 2025
pulisher
Mar 15, 2025

Atossa Therapeutics (NASDAQ:ATOS) Given “Buy” Rating at HC Wainwright - The AM Reporter

Mar 15, 2025
pulisher
Mar 14, 2025

HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS) - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Atossa Genetics stock hits 52-week low at $0.7 amid market challenges - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Atossa Genetics stock hits 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 11, 2025

Nothing is Better Than Atossa Therapeutics Inc (ATOS) stock at the moment - SETE News

Mar 11, 2025
pulisher
Mar 11, 2025

Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Breakthrough: New Breast Cancer Drug Shows 3x Better Survival Rate Than Standard Treatment - StockTitan

Mar 11, 2025
pulisher
Mar 11, 2025

Atossa targets metastatic breast cancer with (Z)-endoxifen - Investing.com

Mar 11, 2025
pulisher
Mar 04, 2025

Atossa Genetics stock hits 52-week low at $0.72 - Investing.com

Mar 04, 2025
pulisher
Feb 25, 2025

Atossa Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com India

Feb 25, 2025
pulisher
Feb 24, 2025

Atossa Therapeutics faces Nasdaq delisting over bid price - Investing.com

Feb 24, 2025
pulisher
Feb 22, 2025

Atossa Therapeutics reports progress in breast cancer treatments - MSN

Feb 22, 2025
pulisher
Feb 20, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 5.8% in January - MarketBeat

Feb 20, 2025
pulisher
Feb 19, 2025

Atossa Therapeutics Inc (ATOS) looking to reclaim success with recent performance - SETE News

Feb 19, 2025

Atossa Therapeutics Inc (ATOS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
자본화:     |  볼륨(24시간):